In a mouse model of MASLD, Cabrera et al. revealed that IGF-1 supplementation may be a more promising therapeutic approach for MASLD compared to GH due to a safer profile and positive outcomes in reducing liver steatosis, lowering serum alanine aminotransferase (ALT) levels, and improving muscle health [44]. This evidence concerns the gene IGF1 and Hepatic steatosis.